Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 25 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 14 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
20(87.0%)
Phase 2
2(8.7%)
N/A
1(4.3%)
23Total
Phase 1(20)
Phase 2(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (25)

Showing 20 of 25 trials
NCT05207995Phase 1Completed

The Treatment of Patients With Type 1 Diabetes Mellitus With Autologous Tolerogenic Dendritic Cells

Role: lead

NCT06167564Not ApplicableUnknown

Allergy Diagnostic Test Based on Microchip Technology

Role: lead

NCT05654766Unknown

Assesment of the Functional Activity of Platelets for the Differential Diagnosis of Thrombocytopathies

Role: lead

NCT05187104Phase 1Unknown

Treatment of Age-related Macular Degeneration Using Retinal Stem and Progenitor Cells

Role: lead

NCT05214014Phase 1Unknown

Treatment of Systemic Sclerosis With Autologous Regulatory Т-cells

Role: lead

NCT05535803Phase 2Unknown

Treatment of Laryngotracheal Stenosis Using Mesenchymal Stem Cells

Role: lead

NCT05520125Phase 1Unknown

Treatment of Patients With Bone Tissue Defects Using Mesenchymal Stem Cells Enriched by Extracellular Vesicles

Role: lead

NCT05520112Phase 1Unknown

Treatment of Recurrent Pregnancy Loss Using Mesenchymal Stem Cells

Role: lead

NCT05210452Phase 1Unknown

Treatment of Alopecia Using Follicular Stem Cells

Role: lead

NCT05167552Phase 1Unknown

Treatment of Allergic Rhinitis and Chronic Polypous Rhinosinusitis With Olfactory Mucosa-derived Mesenchymal Stem Cells

Role: lead

NCT05108077Phase 1Unknown

Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells

Role: lead

NCT05186883Phase 1Unknown

Treatment of Postoperative Hypoparathyroidism Using Cultured Allogenic Parathyroid Cells

Role: lead

NCT04432467Phase 1Completed

Fertility Restoration Using Autologous Mesenchymal Stem Cells

Role: lead

NCT04649840Completed

Estimation of Dynamics of Humoral and Cellular Immunity in COVID-19 Patients

Role: lead

NCT04382547Phase 1Completed

Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells

Role: lead

NCT04426643Phase 1Completed

Treatment of Urinary Incontinence in Men After Prostatectomy With Autologous Adipose-derived Mesenchymal Stem Cells

Role: lead

NCT04446897Phase 1Completed

Treatment of Chronic Medium-severe Periodontitis With Mesenchymal Stem Cells Predifferentiated in Osteogenic Direction

Role: lead

NCT04184232Phase 2Completed

Treatment of Recurrent Bladder Cancer With Dendritic Cells

Role: lead

NCT04184258Phase 1Completed

Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Mesenchymal Stem Cells

Role: lead

NCT04484402Phase 1Completed

Treatment of Patients With Inflammatory-dystrophic Diseases of the Cornea Using Autologous Stem Cells

Role: lead